Table 5.

Treatment-related adverse events.

Adverse events	Any grade	Grade 1	Grade 2	Grade 3	Grade 4
Hand-foot syndrome	16 (14.5%)	9 (8.2%)	5 (4.5%)	2 (1.8%)	0 (0.0%)
Rash	3 (2.7%)	0 (0.0%)	3 (2.7%)	0 (0.0%)	0 (0.0%)
Hoarseness	3 (2.7%)	0 (0.0%)	3 (2.7%)	0 (0.0%)	0 (0.0%)
Nausea/vomiting	13 (11.8%)	13 (11.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Diarrhea	26 (23.7%)	8 (7.3%)	18 (16.4%)	0 (0.0%)	0 (0.0%)
Constipation	14 (12.7%)	10 (9.1%)	4 (3.6%)	0 (0.0%)	0 (0.0%)
Hypertension	17 (15.5%)	4 (3.6%)	10 (9.0%)	3 (2.7%)	0 (0.0%)
Leukopenia	18 (16.3%)	11 (10.0%)	5 (4.5%)	2 (1.8%)	0 (0.0%)
Neutropenia	6 (5.4%)	2 (1.8%)	2 (1.8%)	2 (1.8%)	0 (0.0%)
Thrombocytopenia	36 (32.7%)	24 (21.8)	10 (9.1%)	1 (0.9%)	1 (0.9%)
Anemia	20 (18.1%)	15 (13.6%)	4 (3.6%)	1 (0.9%)	0 (0.0%)
Proteinuria	24 (21.8%)	9 (8.2%)	14 (12.7%)	1 (0.9%)	0 (0.0%)
alanine aminotransferase elevated	27 (24.5%)	23 (20.9%)	4 (3.6%)	0 (0.0%)	0 (0.0%)
aminotransferase elevated	31 (28.1%)	27 (24.5%)	2 (1.8%)	2 (1.8%)	0 (0.0%)
Bilirubin elevated	12 (10.9%)	10 (9.1%)	1 (0.9%)	1 (0.9%)	0 (0.0%)
Hyperlipidemia	21 (19.1%)	21 (19.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Fatigue	7 (6.4%)	7 (6.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Oral mucositis	6 (5.4%)	2 (1.8%)	4 (3.6%)	0 (0.0%)	0 (0.0%)
Creatinine elevated	6 (5.4%)	6 (5.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Arrhythmia	1 (0.9%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
Lactate dehydrogenase elevated	16 (14.5%)	16 (14.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypothyroidism	22 (20.0%)	16 (14.5%)	6 (5.5%)	0 (0.0%)	0 (0.0%)
thyroid-stimulating hormone elevated	25 (22.7%)	20 (18.2%)	5 (4.5%)	0 (0.0%)	0 (0.0%)
Hyperthyroidism	2 (1.8%)	1 (0.9%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
Adrenal cortex hypofunction	1 (0.9%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
Immune-associated pneumonia	1 (0.9%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
Joint pain	3 (2.7%)	3 (2.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Bleeding	6 (5.4%)	6 (5.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hyperuricemia	10 (9.1%)	10 (9.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)